Posted by Michael Wonder on 18 Jan 2016
US FDA accepts for priority review sNDA for Eisai's anti-cancer agent lenvatinib seeking approval for renal cell carcinoma
18 January 2016 - Through this process, the FDA has assigned a PDUFA action date of May 16, 2016, 6 months after the sNDA was submitted.
For more details, go to: http://www.eisai.com/news/news201603.html
